We are live on ! Find out more
IBO icon

Impact BioMedical

12 hedge funds and large institutions have $304K invested in Impact BioMedical in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,873% more capital inflows, than outflows

Capital inflows: $535K | Capital outflows: $18K

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

50% more funds holding

Funds holding: 8 → 12 (+4)

2.43% more ownership

Funds ownership: 0.46% → 2.89% (+2.4%)

Holders
12
Holders Change
+4
Holders Change %
+50%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
–
Closed
1
Calls
$16​K
Puts
–
Net Calls
+$16​K
Net Calls Change
+$16​K

IBO Hedge Fund Activity: Q1 2025 in Review

12 of the 7,492 institutional investors tracked by Wall St. Rank reported a position in Impact BioMedical (IBO) for Q1 2025, worth a combined $304K — up 299% from $76.1K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new IBO positions and 1 closed out — a net gain of 4 holders — while 4 added to existing stakes and 0 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $219K. The largest seller was FNY Investment Advisers, exiting entirely with an estimated $18K sold.

  • 12 institutional investors held Impact BioMedical (IBO) as of Q1 2025, up from 8 in Q4 2024.
  • Funds reported $304K of Impact BioMedical stock for Q1 2025, up 299% quarter-over-quarter.
  • 5 funds opened new Impact BioMedical positions in Q1 2025 and 1 closed out, a net change of +4 holders.
  • The largest Impact BioMedical buyer in Q1 2025 was Vanguard Group, an estimated $219K added.
  • The largest Impact BioMedical seller in Q1 2025 was FNY Investment Advisers, an estimated $18K sold.

Based on aggregated 13F filings for Q1 2025.